Results 121 to 130 of about 11,256 (207)

Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications. [PDF]

Front Oncol
Incognito D, Ciappina G, Ettore G, Ettore C, Incognito GG, Carroccio P, Esposito E, D'Arienzo A, Barraco C, Donato M, Cianci S, Busà B, Di Mauro G, Berretta M.   +13 more
europepmc   +1 more source

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment. [PDF]

Nat Genet
Baeten JT, Chan ICC, Moukarzel L, Petrone GEM, Liu J, Tran D, Tabs J, Tabet I, Agashe S, Nasrollahzadeh E, Vasireddy A, Carter A, Patel M, Stopsack KH, Kantoff PW, Zhou W, Batchi-Bouyou AL, Beeler JS, Mustion G, Pharoah P, Brenton J, Offit K, Barnett E, Li B, Abida W, Schram AM, Weigelt B, Mutch D, Vindigni A, Mullen M, Cruchaga C, Scher H, Levine R, Papaemmanuil E, Machiela MJ, Cadoo K, Link DC, Bolton KL.   +37 more
europepmc   +1 more source

BCLX_L blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. [PDF]

Signal Transduct Target Ther
Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH.   +25 more
europepmc   +1 more source

Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. [PDF]

Cancer Res
Cheng K, Nie H, Zhou W, Guo D, Liao L, Zhang X, Wang C, Zielinski RJ, Gavade JN, Sriramkumar S, Fang Y, Xia S, Wu S, Tang HY, Kossenkov AV, Qi Y, Liu J, Le K, Gruber D, Soth MJ, Post MD, Sood AK, Flückiger-Mangual S, Yap TA, Bitler BG, Zhang R.   +25 more
europepmc   +1 more source

RAUF PARPI SHE'RIYATINING JANRIY YANGILANISHLARI

, 2023
openaire   +2 more sources

9 Caged rucaparib: cancer directed delivery of PARPi

Gynecologic Oncology Reports, 2022
Nicole Marjon, Jun Chen, Morgan E. Diolaiti, Adam Renslo, Alan Ashworth   +4 more
openaire   +1 more source

Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies. [PDF]

J Cancer
Guo J, Wang Y, Li J, Jiang Z.
europepmc   +1 more source

Dissecting the molecular mechanism of nitroalkene-mediated PARPi sensitization.

PARP inhibitors (PARPi) represent a prime example of the fulfillment of the promise of targeted therapy in cancer. However, complex and heterogeneous resistance mechanisms limit their effectiveness.
Braden, Dennis C.
core  

Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions. [PDF]

J Clin Invest
Walmsley CS, Rodriguez A, Konstantinopoulos PA, Shapiro GI, Tolaney SM, Garber JE, Lynce F.   +6 more
europepmc   +1 more source

Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer. [PDF]

Exp Hematol Oncol
Chiappa M, Villa V, Sias F, Grasselli C, Sala L, Canesi S, Marabese M, Mason S, Dibitetto D, Fruscio R, Damia G.   +10 more
europepmc   +1 more source